Who should not use Inspra?

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, those with severe renal impairment (eGFR 5.0 mmol/L), and patients with significant hepatic dysfunction. Caution is also advised for patients on concurrent potassium‑sparing agents.

Inspra

Active Ingredient:: Eplerenone
Origin:: EU

Inspra (Eplerenone)

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral formulation for oral use. It is employed to manage hypertension and to improve outcomes in patients with heart failure, particularly those with reduced ejection fraction. By selectively blocking aldosterone receptors in the distal nephron, it promotes sodium excretion while conserving potassium, contributing to blood pressure reduction and cardiac remodeling mitigation.

GNH India supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Upjohn Eesv

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Inspra, an aldosterone antagonist, is used in cardiovascular conditions where aldosterone excess contributes to disease progression.

Hypertension: lowers blood pressure by promoting natriuresis and potassium retention.
Heart failure: reduces risk of hospitalization and mortality in patients with reduced ejection fraction.
Post‑myocardial infarction: helps lower the incidence of cardiovascular events in patients with left‑ventricular dysfunction.

How It Works

Eplerenone selectively binds to mineralocorticoid receptors in the distal nephron, blocking aldosterone from stimulating sodium reabsorption and potassium excretion. This antagonism leads to increased urinary sodium loss (natriuresis) while retaining potassium, resulting in reduced extracellular fluid volume, lower arterial pressure, and attenuation of pathological cardiac remodeling.

Side Effects

Eplerenone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

Hyperkalaemia: elevated serum potassium levels.
Dizziness or light‑headedness, especially on standing.
Diarrhoea or gastrointestinal upset.
Headache.
Fatigue.
Nausea.

Serious or Rare Side Effects

Severe hyperkalaemia leading to cardiac arrhythmia.
Acute renal impairment or worsening kidney function.
Angioedema or severe allergic reactions.
Hepatic dysfunction or elevated liver enzymes.
Life‑threatening hypotension.
Myocardial infarction in susceptible patients.

Precautions & Warnings

Before initiating Inspra, clinicians should consider several safety measures.

Monitor serum potassium: check levels regularly to avoid hyperkalaemia.
Assess renal function: evaluate creatinine and eGFR before and during therapy.
Use caution in patients with diabetes mellitus, as they may have altered potassium handling.
Avoid in severe hepatic impairment due to reduced metabolism.
Adjust dose in elderly patients or those with moderate renal dysfunction.
Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Eplerenone can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

Potassium‑sparing diuretics (e.g., amiloride, triamterene): risk of severe hyperkalaemia.
ACE inhibitors or ARBs: additive potassium increase and renal effects.
Potassium supplements: may precipitate dangerous hyperkalaemia.
NSAIDs: can impair renal function and raise potassium levels.

Moderate Interactions (Monitor Closely)

Digoxin: altered serum levels due to electrolyte shifts.
Thiazide diuretics: may counteract potassium‑retaining effect.
Lithium: risk of lithium toxicity with altered renal clearance.
Beta‑blockers: may enhance hypotensive response.
Anticoagulants (e.g., warfarin): monitor INR as potassium changes can affect clotting parameters.

Frequently Asked Questions

Inspra contains eplerenone, an aldosterone antagonist prescribed to treat hypertension and to improve outcomes in patients with heart failure, especially those with reduced ejection fraction. It may also be used after myocardial infarction to lower the risk of further cardiovascular events.

Eplerenone blocks mineralocorticoid (aldosterone) receptors in the distal nephron. This inhibition reduces sodium reabsorption and promotes potassium retention, leading to increased urinary sodium loss, lower blood volume, and a reduction in blood pressure and harmful cardiac remodeling.

The specific dose of Inspra is determined by the prescribing clinician based on the individual’s medical condition, kidney function, and serum potassium levels. Typical starting doses may be adjusted over time, but exact regimens should only be set by a qualified health professional.

Safety data for eplerenone in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both eplerenone (Inspra) and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Spironolactone may be less expensive but can cause hormonal side effects, whereas eplerenone often offers a better tolerability profile for patients sensitive to those effects.

Inspra should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Inspra is taken orally, usually with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a full glass of water and follow any specific timing recommendations provided by the healthcare professional.

The most critical safety concerns include severe hyperkalaemia, which can cause cardiac arrhythmias, and acute renal impairment that may worsen kidney function. Patients should be monitored regularly for electrolyte disturbances and renal parameters, especially when initiating therapy or adjusting doses.

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, those with severe renal impairment (eGFR < 30 mL/min/1.73 m²), hyperkalaemia (serum potassium > 5.0 mmol/L), and patients with significant hepatic dysfunction. Caution is also advised for patients on concurrent potassium‑sparing agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.